Brief: Bioarctic's Says As Per Eisai's Simulation Leqembi Sales Will Reach JPY 290 Bln For Financial Year 2026
07/03/2024 05:34
March 7 (Reuters) - BioArctic AB BIOAb.ST :
* BIOARCTIC'S PARTNER EISAI PRESENTS UPDATED SALES
SIMULATION FOR
LEQEMBI® AT ITS ANNUAL PRESS CONFERENCE
* BIOARCTIC AB - LEQEMBI SALES WILL REACH JPY 290 BILLION
FOR
THEIR FINANCIAL YEAR (FY) 2026, WHICH ENDS IN MARCH 2027 AND JPY
1.6 TRILLION IN FY2032
Source text for Eikon: ID:nWkr5jtZSw
Further company coverage: BIOAb.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln